Modest Benefit Triggers Sharp Selloff in Fractyl Health After REMAIN-1 Data
Positive REMAIN-1 data failed to support Fractyl’s valuation. Shares halved on modest effect size, cash runway, and remaining risks.
Positive REMAIN-1 data failed to support Fractyl’s valuation. Shares halved on modest effect size, cash runway, and remaining risks.
Fractyl Health's (GUTS) REMAIN-1 study reveals limited weight maintenance benefits with Revita procedure after stopping GLP-1 medications, raising questions about effectiveness.